CTNM

Contineum Therapeutics, Inc. Class A Common Stock NASDAQ Listed Apr 5, 2024

Healthcare ·Biotechnology ·US · contineum-tx.com

$14.63

Mkt Cap $546.2M

52w Low $3.35 86.9% of range 52w High $16.33

50d MA $13.40 200d MA $11.68

P/E (TTM) -6.1x

EV/EBITDA -3.7x

P/B 1.4x

Debt/Equity 0.0x

ROE -23.0%

P/FCF -5.7x

RSI (14) —

ATR (14) —

Beta 1.39

50d MA $13.40

200d MA $11.68

Avg Volume 280.5K

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

CIK (SEC)

1855175

Phone

(858) 333-5280

10578 Science Center Drive · San Diego, CA 92121 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 5, 2026	AMC	-0.50	-0.49	+2.0%	13.81	+6.5%	+0.5%	-2.4%	-1.0%	+11.7%	-7.5%	—
Oct 30, 2025	AMC	-0.58	-0.45	+22.4%	10.54	+0.9%	+4.5%	-3.3%	-2.4%	+0.5%	+5.5%	—
Aug 5, 2025	AMC	-0.56	-0.62	-10.7%	6.00	+3.0%	+5.5%	+6.3%	-3.9%	-0.6%	+5.0%	—
May 14, 2025	AMC	-0.56	-0.62	-10.7%	3.84	+0.0%	+2.6%	-10.9%	+24.5%	-12.4%	+0.8%	—
Mar 6, 2025	AMC	-0.44	-0.56	-27.3%	6.44	-0.6%	+5.1%	+9.3%	+2.3%	-0.1%	-5.6%	—
Nov 6, 2024	AMC	-0.41	-0.40	+2.4%	17.24	+0.6%	+7.6%	-0.8%	+5.1%	+1.6%	-4.6%	—
Aug 13, 2024	AMC	-0.35	-0.39	-11.4%	16.27	+0.6%	+6.2%	+7.6%	-7.8%	+8.5%	-5.3%	—
May 16, 2024	AMC	-0.46	-3.55	-671.7%	14.96	-1.4%	+3.6%	+1.4%	+1.8%	-0.9%	+1.6%	—
Dec 31, 2023	AMC	—	-0.31	—	—	—	—	—	—	—	—	—
Sep 30, 2023	AMC	—	-0.25	—	—	—	—	—	—	—	—	—
Jun 30, 2023	AMC	—	1.62	—	—	—	—	—	—	—	—	—
Mar 31, 2023	AMC	—	-0.19	—	—	—	—	—	—	—	—	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 6	Baird	Maintains	Outperform → Outperform	—	$13.81	$14.71	+6.5%	+0.5%	-2.4%	-1.0%	+11.7%	-7.5%
Jan 8	Morgan Stanley	Downgrade	Overweight → Equal Weight	—	$9.56	$9.09	-4.9%	-4.1%	+1.5%	-1.5%	+18.9%	+7.9%
Nov 24	Baird	Maintains	Outperform → Outperform	—	$10.95	$10.87	-0.7%	-5.4%	+3.4%	+0.5%	+2.9%	-0.7%
Nov 21	RBC Capital	Maintains	Outperform → Outperform	—	$12.22	$10.97	-10.2%	-10.4%	-5.4%	+3.4%	+0.5%	+2.9%
Aug 18	Morgan Stanley	Maintains	Overweight → Overweight	—	$7.38	$7.44	+0.8%	+9.8%	+14.8%	-4.6%	+13.2%	-1.0%
May 19	Morgan Stanley	Maintains	Overweight → Overweight	—	$3.51	$3.51	+0.0%	+24.5%	-12.4%	+0.8%	+1.3%	-8.7%
May 15	RBC Capital	Maintains	Outperform → Outperform	—	$3.84	$3.84	+0.0%	+2.6%	-10.9%	+24.5%	-12.4%	+0.8%
Mar 7	Baird	Maintains	Outperform → Outperform	—	$6.44	$6.40	-0.6%	+5.1%	+9.3%	+2.3%	-0.1%	-5.6%
Jan 9	RBC Capital	Maintains	Outperform → Outperform	—	—	—	—	—	—	—	—	—
Nov 7	RBC Capital	Maintains	Outperform → Outperform	—	$17.24	$17.34	+0.6%	+7.6%	-0.8%	+5.1%	+1.6%	-4.6%
Aug 14	RBC Capital	Maintains	Outperform → Outperform	—	$16.27	$16.37	+0.6%	+6.2%	+7.6%	-7.8%	+8.5%	-5.3%

Date	Insider	Title	Type	Shares	Price	Value	Owned After	D1%	D5%
May 1, 2026	Lorrain Daniel S.Off	Chief Scientific Officer	Sell	300	$13.84	$4K	143,542	+7.20%	-0.68%
May 1, 2026	Lorrain Daniel S.Off	Chief Scientific Officer	Sell	3,870	$13.06	$51K	143,842	+7.20%	-0.68%

Data updated apr 25, 2026 3:44am · Source: massive.com